Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Доксициклинассоциированный лекарственный эзофагит: современные фармакологические возможности решения клинической проблемы
Доксициклинассоциированный лекарственный эзофагит: современные фармакологические возможности решения клинической проблемы
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Wright LT, Schreiber H. The Clinical Value of Aureomycin. J Natl Med Assoc 1949; 41 (5): 195–201.
2. Boothe JH, Morton II J, Petisi JP et al. J Am Chem Soc 1953; 75 (18): 4621.
3. Biffi G, Boretti G, Marco A, Pennela P. Metabolic behavior and chlortetracycline production by Streptornyces aureofaciens in liquid culture. Appl Microbiol 1954; 2: 288–93.
4. Zakeri B, Wright GD. Chemical biology of tetracycline antibiotics. Biochem Cell Biol 2008; 86: 124–1316.
5. Практическое руководство по антиинфекционной химиотерапии под ред. Л.С.Страчунского, Ю.Б.Белоусова, С.Н.Козлова. М., 2002.
6. Phimda K. Doxycycline versus azithromycin for treatment of leptospirosis and scrub typhus. Antimicrob Agents Chemother 2007; 51 (9): 3259–63.
7. Griffith KS, Lewis LS, Mali S, Parise ME.Treatment of malaria in the United States: a systematic review. JAMA 2007; 297 (20): 2264–77.
8. Chuen-Yen Lau, Azhar K. Qureshi Azithromycin Versus Doxycycline for Genital Chlamydial Infections: A Meta-Analysis of Randomized Clinical Trials. Sexually Transmitted Diseases 2002; 29: 497–502.
9. Krausse R, Schubert S. In-Vitro Activities of Tetracyclines, Macrolides, Fluoroquinolones and Clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated in Germany over 20 years. Clin Microbiol Infect 2009 [Epub ahead of print].
10. Kozlov RS. Proceedings of the 43rd ICAAC. Chicago, Illinois, USA, 2003; p. 130 (Abstr. C2–937 c доп.).
11. Segelnick SL, Weinberg MA. Recognizing Doxycycline-Induced Esophageal Ulcers in Dental Practice: A Case Report and Review. J Am Dent Assoc 2008; 139: 581–5.
12. Антонова М.Д. Применение текстильных имплантатов из полиэфирного полотна для хирургического лечения отслойки сетчатки. Автореф. дис. ... канд. мед. наук. М., 2007.
13. Berman B, Perez OA, Zell D. Update on rosacea and anti-inflammatory-dose doxycycline. Drugs Today (Barc) 2007; 43 (1): 27–34.
14. Akhyani M, Ehsani AH, Ghiasi M, Jafari AK. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. Int J Dermatol 2008; 47 (3): 284–8.
15. Carlborg B, Densert O, Lindqvist C. Tetracycline induced esophageal ulcers: a clinical and experimental study. Laryngoscope 1983; 93: 184–7.
16. Bott SJ, McCallum RW. Medicine-induced oesophageal injury. Survey of the literature. Med Toxicol 1986; 1: 449–57.
17. Kikendall JW. Pill esophagitis. J Clin Gastroenterol 1999; 28: 298–305.
18. Boyce HW. Drug-induced esophageal damage: diseases of medical progress. Gastrointest Endoscopy 1998; 47: 547–50.
19. Kikendall JW, Friedman AC, Oyewole MA et al. Pill-induced esophageal injury: case reports and review of the medical literature. Dig Dis Sci 1983; 28 (2): 174–82.
20. Carlborg B, Densert O. Medikamentella esofagusstrikturer. Lakartidningen 1978; 75: 4609–11.
21. Wright V. The oesophagus. Ed. P.Walker, J.Durie, J.Hamilton. Pediatric gastrointestinal disease: pathophysiology, diagnosis and management. Vol. I. Philadelphia: BC Decker Inc., 1991: p. 375–6.
22. Jaspersen D. Drug-Induced Oesophageal Disorders Pathogenesis, Incidence, Prevention and Management. Drug Safety 2000; 22 (3): 237–49.
23. Al Mofarreh MA, Al Mofleh IA. Doxycycline-induced esophageal ulcerations. Saudi J Gastroenterol 1998; 4 (1): 20–4.
24. Bott S, Prakash C, McCallum RW. Medication-induced esophageal injury: survey of the literature. Am J Gastroenterol 1987; 82 (8): 758–63.
25. Kikendall JW. Pill-induced esophageal injury. Gastroenterol Clin North Am 1991; 20: 835–46.
26. Akbayir N, Alkim C, Erdem L et al. A case report of doxycycline induced esophageal and gastric ulcer. Turk J Gastroenterol 2002; 13 (4): 232–5.
27. Kadayifci A, Gulsen MT, Koruk M, Savas MC. Doxycycline-induced pill esophagitis. Diseases of the Esophagus 2004; 17: 168–71.
28. Levine MS. Drug-induced disorders of the esophagus. Abdom Imaging 1999; 24: 3–8.
29. Shortsleeve MJ, Levine MS. Herpes oesophagitis in otherwise healthy patients: clinical and radiographic findings. Radiology 1992; 182: 859–61.
30. Levine MS, Macones AJ, Laufer I. Candida oesophagitis – accuracy of radiographic diagnosis. Radiology 1985; 154: 581–7.
31. Gobel V, Long BW, Richter G. Aphthous ulcers in the oesophagus with Crohn colitis. AJR 1981; 137: 872–3.
32. Weerda H, Brand ET. Stevens-Johnson syndrome with oesophagitis. HNO 1974; 22: 246–8.
33. Sur S, Levine MS, Kowalski TE et al. Giant ulcers of the oesophagus in patients with human immunodeficiency virus: clinical, radiographic, and pathologic findings. Radiology 1995; 194: 447–51.
34. Al-Mofarreh MA, Al-Mofleh IA. Esophageal ulceration complicating doxycycline therapy. World J Gastroenterol 2003; 15; 9 (3): 609–11.
35. Morris TJ. Doxycycline-induced esophageal ulceration in the U.S. military service. Mil Med 2000; 165 (4): 316–9.
36. Carlborg B, Farmer JC. Esophageal corrosion tests with doxycycline monohydrate tablets. Curr Thera Res 1983; 34 (1): 110–6.
37. Malmborg AS. Bioavailability of doxycycline monohydrate.
A comparison with equivalent doses of doxycycline hydrochloride. Chemotherapy 1984; 30 (2): 76–80.
38. Saano V, Paronen P, Peura P. Bioavailability of doxycycline from dissolved doxycycline hydrochloride tablets – comparison to solid form hydrochloride tablets and dissolved monohydrate tablets. Int J Clin Pharmacol Ther Toxicol 1990; 28 (11): 471–4.
39. Bogardus JB, Blackwood RK. Dissolution rates of doxycycline free base and hydrochloride salts. J Pharm Sci 1979; 68 (9): 1183–4.
40. Мавров Г.И. Тетрациклиновые антибиотики в лечении больных с хламидийными инфекциями: как выбрать оптимальный препарат. Венерологiя. 2007; 1: 81–4.
41. Проценко Т.В., Корчак И.В., Проценко О.А., Стинская Я.Б. Юнидокс солютаб в комплексном лечении больных угревой болезнью. Косметологiя. 2005; 2: 51–2.
42. Мавров Г.И., Бондаренко Г.М. Доксициклина моногидрат в комплексном лечении болезни Рейтера. Венерологiя. 2004; 2: 78–81.
43. Кисина В.И. Применение препарата Юнидокс Солютаб в терапии урогенитального хламидиоза. Вест. дерматол. и венерол. 2000; 2: 54–55.
44. Карпов О.И. Клиническая фармакология растворимой формы амоксициллина/клавуланата. Фарматека. 2005; 12.
45. Ушкалова Е. Значение лекарственных форм для рациональной антибиотикотерапии. Лекарственная форма Солютаб. Врач. 2007; 3: 1–4.
2. Boothe JH, Morton II J, Petisi JP et al. J Am Chem Soc 1953; 75 (18): 4621.
3. Biffi G, Boretti G, Marco A, Pennela P. Metabolic behavior and chlortetracycline production by Streptornyces aureofaciens in liquid culture. Appl Microbiol 1954; 2: 288–93.
4. Zakeri B, Wright GD. Chemical biology of tetracycline antibiotics. Biochem Cell Biol 2008; 86: 124–1316.
5. Практическое руководство по антиинфекционной химиотерапии под ред. Л.С.Страчунского, Ю.Б.Белоусова, С.Н.Козлова. М., 2002.
6. Phimda K. Doxycycline versus azithromycin for treatment of leptospirosis and scrub typhus. Antimicrob Agents Chemother 2007; 51 (9): 3259–63.
7. Griffith KS, Lewis LS, Mali S, Parise ME.Treatment of malaria in the United States: a systematic review. JAMA 2007; 297 (20): 2264–77.
8. Chuen-Yen Lau, Azhar K. Qureshi Azithromycin Versus Doxycycline for Genital Chlamydial Infections: A Meta-Analysis of Randomized Clinical Trials. Sexually Transmitted Diseases 2002; 29: 497–502.
9. Krausse R, Schubert S. In-Vitro Activities of Tetracyclines, Macrolides, Fluoroquinolones and Clindamycin against Mycoplasma hominis and Ureaplasma ssp. isolated in Germany over 20 years. Clin Microbiol Infect 2009 [Epub ahead of print].
10. Kozlov RS. Proceedings of the 43rd ICAAC. Chicago, Illinois, USA, 2003; p. 130 (Abstr. C2–937 c доп.).
11. Segelnick SL, Weinberg MA. Recognizing Doxycycline-Induced Esophageal Ulcers in Dental Practice: A Case Report and Review. J Am Dent Assoc 2008; 139: 581–5.
12. Антонова М.Д. Применение текстильных имплантатов из полиэфирного полотна для хирургического лечения отслойки сетчатки. Автореф. дис. ... канд. мед. наук. М., 2007.
13. Berman B, Perez OA, Zell D. Update on rosacea and anti-inflammatory-dose doxycycline. Drugs Today (Barc) 2007; 43 (1): 27–34.
14. Akhyani M, Ehsani AH, Ghiasi M, Jafari AK. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. Int J Dermatol 2008; 47 (3): 284–8.
15. Carlborg B, Densert O, Lindqvist C. Tetracycline induced esophageal ulcers: a clinical and experimental study. Laryngoscope 1983; 93: 184–7.
16. Bott SJ, McCallum RW. Medicine-induced oesophageal injury. Survey of the literature. Med Toxicol 1986; 1: 449–57.
17. Kikendall JW. Pill esophagitis. J Clin Gastroenterol 1999; 28: 298–305.
18. Boyce HW. Drug-induced esophageal damage: diseases of medical progress. Gastrointest Endoscopy 1998; 47: 547–50.
19. Kikendall JW, Friedman AC, Oyewole MA et al. Pill-induced esophageal injury: case reports and review of the medical literature. Dig Dis Sci 1983; 28 (2): 174–82.
20. Carlborg B, Densert O. Medikamentella esofagusstrikturer. Lakartidningen 1978; 75: 4609–11.
21. Wright V. The oesophagus. Ed. P.Walker, J.Durie, J.Hamilton. Pediatric gastrointestinal disease: pathophysiology, diagnosis and management. Vol. I. Philadelphia: BC Decker Inc., 1991: p. 375–6.
22. Jaspersen D. Drug-Induced Oesophageal Disorders Pathogenesis, Incidence, Prevention and Management. Drug Safety 2000; 22 (3): 237–49.
23. Al Mofarreh MA, Al Mofleh IA. Doxycycline-induced esophageal ulcerations. Saudi J Gastroenterol 1998; 4 (1): 20–4.
24. Bott S, Prakash C, McCallum RW. Medication-induced esophageal injury: survey of the literature. Am J Gastroenterol 1987; 82 (8): 758–63.
25. Kikendall JW. Pill-induced esophageal injury. Gastroenterol Clin North Am 1991; 20: 835–46.
26. Akbayir N, Alkim C, Erdem L et al. A case report of doxycycline induced esophageal and gastric ulcer. Turk J Gastroenterol 2002; 13 (4): 232–5.
27. Kadayifci A, Gulsen MT, Koruk M, Savas MC. Doxycycline-induced pill esophagitis. Diseases of the Esophagus 2004; 17: 168–71.
28. Levine MS. Drug-induced disorders of the esophagus. Abdom Imaging 1999; 24: 3–8.
29. Shortsleeve MJ, Levine MS. Herpes oesophagitis in otherwise healthy patients: clinical and radiographic findings. Radiology 1992; 182: 859–61.
30. Levine MS, Macones AJ, Laufer I. Candida oesophagitis – accuracy of radiographic diagnosis. Radiology 1985; 154: 581–7.
31. Gobel V, Long BW, Richter G. Aphthous ulcers in the oesophagus with Crohn colitis. AJR 1981; 137: 872–3.
32. Weerda H, Brand ET. Stevens-Johnson syndrome with oesophagitis. HNO 1974; 22: 246–8.
33. Sur S, Levine MS, Kowalski TE et al. Giant ulcers of the oesophagus in patients with human immunodeficiency virus: clinical, radiographic, and pathologic findings. Radiology 1995; 194: 447–51.
34. Al-Mofarreh MA, Al-Mofleh IA. Esophageal ulceration complicating doxycycline therapy. World J Gastroenterol 2003; 15; 9 (3): 609–11.
35. Morris TJ. Doxycycline-induced esophageal ulceration in the U.S. military service. Mil Med 2000; 165 (4): 316–9.
36. Carlborg B, Farmer JC. Esophageal corrosion tests with doxycycline monohydrate tablets. Curr Thera Res 1983; 34 (1): 110–6.
37. Malmborg AS. Bioavailability of doxycycline monohydrate.
A comparison with equivalent doses of doxycycline hydrochloride. Chemotherapy 1984; 30 (2): 76–80.
38. Saano V, Paronen P, Peura P. Bioavailability of doxycycline from dissolved doxycycline hydrochloride tablets – comparison to solid form hydrochloride tablets and dissolved monohydrate tablets. Int J Clin Pharmacol Ther Toxicol 1990; 28 (11): 471–4.
39. Bogardus JB, Blackwood RK. Dissolution rates of doxycycline free base and hydrochloride salts. J Pharm Sci 1979; 68 (9): 1183–4.
40. Мавров Г.И. Тетрациклиновые антибиотики в лечении больных с хламидийными инфекциями: как выбрать оптимальный препарат. Венерологiя. 2007; 1: 81–4.
41. Проценко Т.В., Корчак И.В., Проценко О.А., Стинская Я.Б. Юнидокс солютаб в комплексном лечении больных угревой болезнью. Косметологiя. 2005; 2: 51–2.
42. Мавров Г.И., Бондаренко Г.М. Доксициклина моногидрат в комплексном лечении болезни Рейтера. Венерологiя. 2004; 2: 78–81.
43. Кисина В.И. Применение препарата Юнидокс Солютаб в терапии урогенитального хламидиоза. Вест. дерматол. и венерол. 2000; 2: 54–55.
44. Карпов О.И. Клиническая фармакология растворимой формы амоксициллина/клавуланата. Фарматека. 2005; 12.
45. Ушкалова Е. Значение лекарственных форм для рациональной антибиотикотерапии. Лекарственная форма Солютаб. Врач. 2007; 3: 1–4.
Авторы
Ю.Б.Белоусов1, А.Н.Данилов1, С.К.Зырянов1, С.А.Рачина2
1. ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава РФ;
2. НИИ антимикробной химиотерапии ГБОУ ВПО Смоленская государственная медицинская академия Минздрава РФ
1. ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава РФ;
2. НИИ антимикробной химиотерапии ГБОУ ВПО Смоленская государственная медицинская академия Минздрава РФ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.